Allergy
Capital
Treating allergies with immunotherapy
Medicines do not cure allergies. Immunotherapy injections
(also known as desensitization or allergy shots) can improve symptom
severity, reduce medication use and may even reduce the risk of
developing new allergies in the future.
Revised 27 January 2003




IMPORTANT The information provided is of a general
nature and should not be used as a substitute for professional
advice. If you think you may suffer from an allergic or other
disease that requires attention, you should discuss it with your
family doctor.
Allergies last a long time
Hay fever lasts 10-20 years in most people and those suffering
from asthma as adults are unlikely to grow out of it. Medicines
may help you to live with allergies but will not cure these problems.
Furthermore, it is not always possible to avoid allergic triggers,
such as grass pollens. Desensitization (immunotherapy) is the
only way of "teaching" the immune system to tolerate
allergic triggers. It is effective in most people with hay
fever and often helps those with asthma.
Immunotherapy is also an essential part of managing people with
dangerous allergic reactions (anaphylaxis)
to bee and wasp stings.
Immunotherapy: science or quackery?
Immunology is a young science whose origins lie in the study
of infections in the late 19th century. It was not until the 1870's
that grass pollens were identified as the likely trigger for seasonal
hay fever in the UK. Skin allergy testing
only became an accepted technique around 1910. It took until
1965 before IgE was identified, and another 5 years until it was
found bound to tissue mast cells (see article on "What
is Allergy?"). Given that the first report of immunotherapy
appeared in 1911 in the Lancet, it is clear that science has lagged
behind clinical practice by many decades. In fact, it is really
only in the last 10-15 years that we have had a good scientific
explanation for how it helps reduce the severity of some allergies.
How does immunotherapy work?
Our immune system responds to substances in our environment that
we eat, drink or breathe in, but only "allergic" people
develop an "allergic" immune response. Allergy injections
alter the way in which the immune system reacts to allergen. By
giving small but increasing amounts of allergen at regular intervals,
tolerance increases. The end result is that you become "immune"
to the allergens, so that you can tolerate them with fewer or
no symptoms. This process is also known as specific immunotherapy,
because one is trying to turn off one or more specific
allergic responses. In other words, if you have injections
for grass pollen allergy, it will not affect your allergy to cat
or house dust mite or vice versa. In general, one tries to switch
off one or two allergic responses at a time. The higher the dose
tolerated without significant side-effects, the more likely is
treatment successful.
Who should consider immunotherapy?
- Patient with dangerous allergic reactions (anaphylaxis)
to stinging insects like bee, wasp
allergy and the imported South American Fire Ant
- Patients with hay fever or asthma in whom:
-It is difficult or impossible to successfully avoid the cause
-Medication does not work
-Medication causes side-effects
-As an alternative to medication
Immunotherapy is only occasionally recommended for the
treatment of atopic eczema. It is not
currently recommended for the treatment of food allergy, or for
insect or tick bites, because it doesn't appear to work. There
are commercial extracts available for the imported South American
Fire Ant which was identified for the first time in Australia
during 2002. Unfortunately, there are no commercially available
vaccines for switching off allergy to the Australian Jumper Ant,
although research in this area is currently occurring in Australia.
How old do you need to be to have injections?
There are a number of studies of immunotherapy injections in both
children and adults, and it works in both groups. When dangerous
allergic reactions to insect stings occur, immunotherapy may be
advised regardless of age. Comfort may be increased by using ice-packs
and local anaesthetic cream (like EMLA) 1-2 hours before the injection.
In older patients, immunotherapy may not be recommended as they
may have a reduced capacity to cope with side-effects, particularly
if they suffer from major heart or lung problems
When treating non-dangerous allergies like hay fever, however,
young children are generally hard to convince of the benefits!
Nevertheless, young teenagers normally tolerate the slight discomfort
quite well.
Desensitization and pregnancy: It is normally recommended
to NOT start desensitization if you is pregnant. Some doctors
also recommend stopping treatment if you became pregnant.
This is not because immunotherapy has been shown to cause malformations
in the developing baby. The concern is that if mum has severe
allergic side-effects after an injection, then the baby's oxygen
supply may be interfered with.
How well do they work?
About 3 in 4 patients with hay fever experience significant improvement
with immunotherapy. Sometimes symptoms are reduced rather than
abolished. In that case you may need medication as well.
In stinging insect allergy (bee, wasp), the protection against
further dangerous allergic reactions to stinging insects is variously
quoted at between 80 and 95 %.
Recent studies in children suggest that if immunotherapy is
commenced soon after allergies first develop, it may actually
reduce the risk of developing allergic reactions to other allergens,
and even reduce the risk of later developing asthma.

How is it
done?
- Small diabetic insulin syringes are used to inject commercial
allergen extracts.
- Injections are normally given into the loose ("floppy")
tissue over the back of the upper arm, half way between the shoulder
and elbow.
- Injections are given under the skin ("subcutaneous").
- This is the least painful place to inject allergen, as there
are few nerve endings in the skin.
- When given correctly, the injections should be slightly uncomfortable.
- They are not normally painful and are usually well
tolerated by adults and teenagers.
- Some doctors may advise you to take an antihistamine a few
hours before each injection to reduce the likelihood of local
discomfort and other side-effects.
Are
there lots of injections?
Yes! Allergy injections are started at very low doses. The dose
is gradually increased on a regular (and usually weekly) basis,
until a "maintenance" dose is reached. This usually
means four to six months of weekly injections. It is a bit like
climbing a staircase. Once the top maintenance dose is reached,
the injections are administered less often, although still on
a regular basis. Maintenance injections are normally given once
per month for a few years.
What is pre-seasonal immunotherapy?
Some allergy specialists use a form of treatment called pre-seasonal
immunotherapy. Injections are given approximately once per week
during winter (usually June, July, August in Australia), stopping
just before the spring hay fever season begins. This repeated
each year for 3 - 5 years, and increasing improvement is seen
year by year.
How long will you be having injections?
This form of treatment is not a "quick fix". You need
to be committed for it to work, and to cooperate with you doctor
to reduce the risk of side effects. If immunotherapy helps, it
is normally recommended that maintenance doses be continued for
an extra 3 to 5 years. This decreases the chance that your allergies
will return. While this is a lot of trouble, you need to remember
that you are treating a condition that might otherwise last many
times that period of time.
Can you still use medicines as well?
You can still use all your allergy and asthma medicines at the
same time in the usual way.
How long will the benefit last?
There are only a few long-term studies of how long the benefit
of treatment lasts after the injections are stopped. They suggest
that most people remain well for at least 3 years after stopping
treatment. "Anecdotal experience" suggest that the benefit
often lasts a lot longer, and that returning allergies are often
milder than that experienced originally.
What happens if my allergies return after stopping injections?
You can use medication or restart immunotherapy if necessary.
Are other methods of immunotherapy useful?
In some countries, particularly in Europe, there is a strong tradition
of undertaking immunotherapy using oral vaccines or sublingual
drops. While there has been some interesting research in this
area in recent years, the effectiveness of this form of treatment
is difficult to compare with standard injected immunotherapy.
For this reason, it is not generally recommended in Australia
at this point in time.
New developments in immunotherapy
Recent animal and human studies using fragments of DNA attached
to allergen offer the prospect of stimulating a potent anti-allergic
immune response without the risk of allergic reactions.These vaccines
are currently being trialed in humans, and have shown promising
results in animal studies. Such methods offer the possibility
of developing preventative allergy "vaccines" that might
prevent the onset of disease if administered to children at high
risk. From time to time, studies describing more convenient and
less frequent treatments have been described, but these are not
currently commercially available.
Side effects of desensitization
- A small "diabetic" needle is used which may be
uncomfortable, but not very painful.
- Everyone gets an itchy lump at the site of injection
- Your doctor may need to adjust the dose if the reactions
are more severe.
To reduce the risks of side effects, you will normally advised
to:
- wait in your doctor's surgery after each injection
- avoid exercising for a few hours afterwards
- avoid some heart and blood pressure medicines (like beta-blockers)
that may reduce the safety of the treatment.
- avoid starting this form of therapy if you are pregnant
Safety aspects of immunotherapy are discussed in an
accompanying article.
References
- Norman PS. Immunotherapy: Past and Present.
J Allergy Clin Immunol 1998; 102: 1-10.
- Platts-Mills T et al. Future directions for
allergen immunotherapy. J Allergy Clin Immunol 1998; 102: 335-43.
- Abramson MJ et al. Is allergen immunotherapy
effective in asthma? A meta-analysis of randomised controlled
trials. Am J Respir Crit Care Med 1995; 151: 969-74.
- WHO Position Paper. Allergen immunotherapy:
therapeutic vaccines for allergic disease. Allergy 1998; 53:
Supplement 44.
- Nicklas R et al. Practice parameters for
allergen immunotherapy. J Allergy Clin Immunol 1996; 6: 1001-11.
- Greineder DK. Risk management in allergen
immunotherapy. J Allergy Clin Immunol 1996; 98: S330-4.
- Specific allergen immunotherapy for asthma.
A Position paper of the Thoracic Society of Australia and New
Zealand and the Australasian Society of Clinical Immunology and
Allergy. Med J Aust 1997; 167: 540-4.
- Abramson, M. J., R. M. Puy, et al. (2000).
"Allergen immunotherapy for asthma." Cochrane Database
Syst Rev 2.
- Arvidsson, M. B., O. Lowhagen, et al. (2002).
"Effect of 2-year placebo-controlled immunotherapy on airway
symptoms and medication in patients with birch pollen allergy."
J Allergy Clin Immunol 109(5 Pt 1): 777-83.
- Asero, R. (1998). "Effects of birch
pollen-specific immunotherapy on apple allergy in birch pollen-hypersensitive
patients." Clin Exp Allergy 28(11): 1368-73.
- Bousquet, J., R. Lockey, et al. (1998). "Allergen
immunotherapy: therapeutic vaccines for allergic diseases. World
Health Organization. American academy of Allergy, Asthma and
Immunology." Ann Allergy Asthma Immunol 81(5 Pt 1): 401-5.
- Bousquet, J., R. Lockey, et al. (1998). "Allergen
immunotherapy: therapeutic vaccines for allergic diseases. A
WHO position paper." J Allergy Clin Immunol 102(4 Pt 1):
558-62.
- Bousquet, J., P. Demoly, et al. (2001). "Specific
immunotherapy in rhinitis and asthma." Ann Allergy Asthma
Immunol 87(1 Suppl 1): 38-42.
- Brockow, K., M. Kiehn, et al. (1997). "Efficacy
of antihistamine pretreatment in the prevention of adverse reactions
to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled
trial." J Allergy Clin Immunol 100(4): 458-63.
- Des Roches, A., L. Paradis, et al. (1997).
"Immunotherapy with a standardized Dermatophagoides pteronyssinus
extract. VI. Specific immunotherapy prevents the onset of new
sensitizations in children." J Allergy Clin Immunol 99(4):
450-3.
- Di Bernardino, C., F. Di Bernardino, et al.
(2002). "A case control study of dermatophagoides immunotherapy
in children below 5 years of age." Allerg Immunol (Paris)
34(2): 56-9.
- Durham, S. R. and S. J. Till (1998). "Immunologic
changes associated with allergen immunotherapy." J Allergy
Clin Immunol 102(2): 157-64.
- Ebner, C., U. Siemann, et al. (1997). "Immunological
changes during specific immunotherapy of grass pollen allergy:
reduced lymphoproliferative responses to allergen and shift from
TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass
pollen allergen." Clin Exp Allergy 27(9): 1007-15.
- Eng, P. A., M. Reinhold, et al. (2002). "Long-term
efficacy of preseasonal grass pollen immunotherapy in children."
Allergy 57(4): 306-12.
- Ewan, P. W. (2001). "New insight into
immunological mechanisms of venom immunotherapy." Curr Opin
Allergy Clin Immunol 1(4): 367-74.
- Fan, H. W., L. F. Marcopito, et al. (1999).
"Sequential randomised and double blind trial of promethazine
prophylaxis against early anaphylactic reactions to antivenom
for bothrops snake bites." Bmj 318(7196): 1451-2.
- Hedlin, G., S. Wille, et al. (1999). "Immunotherapy
in children with allergic asthma: effect on bronchial hyperreactivity
and pharmacotherapy." J Allergy Clin Immunol 103(4): 609-14.
- Jacobsen, L. (2001). "Preventive aspects
of immunotherapy: prevention for children at risk of developing
asthma." Ann Allergy Asthma Immunol 87(1 Suppl 1): 43-6.
- Koppler, H., J. Heymanns, et al. (2001).
"Dose reduction of steroid premedication for paclitaxel:
no increase of hypersensitivity reactions." Onkologie 24(3):
283-5.
- Marshall, G. D., Jr. and P. L. Lieberman
(1991). "Comparison of three pretreatment protocols to prevent
anaphylactoid reactions to radiocontrast media." Ann Allergy
67(1): 70-4.
- Moller, C., S. Dreborg, et al. (2002). "Pollen
immunotherapy reduces the development of asthma in children with
seasonal rhinoconjunctivitis (the PAT-study)." J Allergy
Clin Immunol 109(2): 251-6.
- Moverare, R., E. Vesterinen, et al. (2001).
"Pollen-specific rush immunotherapy: clinical efficacy and
effects on antibody concentrations." Ann Allergy Asthma
Immunol 86(3): 337-42.
- Muller, U. R. (2001). "New developments
in the diagnosis and treatment of hymenoptera venom allergy."
Int Arch Allergy Immunol 124(4): 447-53.
- Muller, U., Y. Hari, et al. (2001). "Premedication
with antihistamines may enhance efficacy of specific- allergen
immunotherapy." J Allergy Clin Immunol 107(1): 81-6.
- Naclerio, R. M., D. Proud, et al. (1997).
"A double-blind study of the discontinuation of ragweed
immunotherapy." J Allergy Clin Immunol 100(3): 293-300.
- Nielsen, L., C. R. Johnsen, et al. (1996).
"Antihistamine premedication in specific cluster immunotherapy:
a double- blind, placebo-controlled study." J Allergy Clin
Immunol 97(6): 1207-13.
- Pichler, C. E., A. Helbling, et al. (2001).
"Three years of specific immunotherapy with house-dust-mite
extracts in patients with rhinitis and asthma: significant improvement
of allergen- specific parameters and of nonspecific bronchial
hyperreactivity." Allergy 56(4): 301-6.
- Portnoy, J., K. Bagstad, et al. (1994). "Premedication
reduces the incidence of systemic reactions during inhalant rush
immunotherapy with mixtures of
- allergenic extracts." Ann Allergy 73(5):
409-18.
- Reimers, A., Y. Hari, et al. (2000). "Reduction
of side-effects from ultrarush immunotherapy with honeybee venom
by pretreatment with fexofenadine: a double-blind, placebo- controlled
trial." Allergy 55(5): 484-8.
- Rolland, J. and R. O'Hehir (1998). "Immunotherapy
of allergy: anergy, deletion, and immune deviation." Curr
Opin Immunol 10(6): 640-5.
- Rolland, J. M., J. Douglass, et al. (2000).
"Allergen immunotherapy: current and new therapeutic strategies."
Expert Opin Investig Drugs 9(3): 515-27.
- Ross, R. N., H. S. Nelson, et al. (2000).
"Effectiveness of specific immunotherapy in the treatment
of asthma: a meta-analysis of prospective, randomized, double-blind,
placebo- controlled studies." Clin Ther 22(3): 329-41.
- Schadlich, P. K. and J. G. Brecht (2000).
"Economic evaluation of specific immunotherapy versus symptomatic
treatment of allergic rhinitis in Germany." Pharmacoeconomics
17(1): 37-52.
- Varney, V. A., J. Edwards, et al. (1997).
"Clinical efficacy of specific immunotherapy to cat dander:
a double- blind placebo-controlled trial." Clin Exp Allergy
27(8): 860-7.
- Winther, L., H. J. Malling, et al. (2000).
"Allergen-specific immunotherapy in birch- and grass-pollen-allergic
rhinitis. I. Efficacy estimated by a model reducing the bias
of annual differences in pollen counts." Allergy 55(9):
818-26.
- Norman PS. Immunotherapy: Past and Present.
J Allergy Clin Immunol 1998; 102: 1-10.
2. Platts-Mills T et al. Future directions for allergen immunotherapy.
J Allergy Clin Immunol 1998; 102: 335-43
- Nicklas R et al. Practice parameters for
allergen immunotherapy. J Allergy Clin Immunol 1996; 6: 1001-11.
6. Greineder DK. Risk management in allergen immunotherapy. J
Allergy Clin Immunol 1996; 98: S330-4.
- Sturm G, Kranke B, Rudolph C, Aberer W. Rush
Hymenoptera venom immunotherapy: a safe and practical protocol
for high-risk patients. J Allergy Clin Immunol. 2002 Dec;110(6):928-33.
- Burton MD, Papalia L, Eusebius NP, O'Hehir
RE, Rolland JM. Characterization of the human T cell response
to rye grass pollen allergens Lol p 1 and Lol p 5. Allergy. 2002
Dec;57(12):1136-44.
- Larche M. Anti-T-cell strategies in the treatment
of allergic disease. Allergy. 2002;57 Suppl 72:20-3.
- Valenta R. The future of antigen-specific
immunotherapy of allergy. Nat Rev Immunol. 2002 Jun;2(6):446-53.
Review.
- Bodtger U, Poulsen LK, Jacobi HH, Malling
HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy
- a one-year, randomised, double-blind, placebo-controlled study.
Allergy. 2002 Apr;57(4):297-305.
- Tankersley MS, Walker RL, Butler WK, Hagan
LL, Napoli DC, Freeman TM.
Safety and efficacy of an imported fire ant rush immunotherapy
protocol with and
without prophylactic treatment.
J Allergy Clin Immunol. 2002 Mar;109(3):556-62. Spiegelberg HL,
Raz E.
DNA-based approaches to the treatment of allergies. Curr Opin
Mol Ther. 2002 Feb;4(1):64-71. Review.
- Machin IS, Robaina JCG, Bonnet C, de Blas
C, Fernandez-Caldas E, Trivino MS, de la Morin FT. Immunotherapy
units: a follow-up study. J Investig Allergol Clin Immunol. 2001;11(3):167-71.
- Wuthrich B, Gumowski PL, Fah J, Hurlimann
A, Deluze C, Andre C, Fadel R, Carat F. Safety and efficacy of
specific immunotherapy with standardized allergenic
extracts adsorbed on aluminium hydroxide. J Investig Allergol
Clin Immunol. 2001;11(3):149-56.
- Purello-D'Ambrosio F, Gangemi S, Merendino
RA, Isola S, Puccinelli P,
Parmiani S, Ricciardi L. Prevention of new sensitizations in
monosensitized subjects submitted to specific immunotherapy or
not. A retrospective study. Clin Exp Allergy. 2001 Aug;31(8):1295-302.
- Leynadier F, Banoun L, Dollois B, Terrier
P, Epstein M, Guinnepain MT, Firon D, Traube C, Fadel R, Andre
C. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen
extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled
study. Clin Exp Allergy. 2001 Jul;31(7):988-96.
- Tabar AI, Lizaso MT, Garcia BE, Echechipia
S, Olaguibel JM, Rodriguez A. Tolerance of immunotherapy with
a standardized extract of Alternaria tenuis in patients with
rhinitis and bronchial asthma. J Investig Allergol Clin Immunol.
2000 Nov-Dec;10(6):327-33.
- Tighe H, Takabayashi K, Schwartz D, Van Nest
G, Tuck S, Eiden JJ, Kagey-Sobotka A, Creticos PS, Lichtenstein
LM, Spiegelberg HL, Raz E. Conjugation of immunostimulatory DNA
to the short ragweed allergen amb a 1 enhances its immunogenicity
and reduces its allergenicity. J Allergy Clin Immunol. 2000 Jul;106(1
Pt 1):124-34.
- Ibanez Sendin MD. [Evaluation of the pediatric
aspects of the WHO document and meta-analysis of immunotherapy]
Allergol Immunopathol (Madr). 2000 May-Jun;28(3):82-9. Review.
- Mastrandrea F, Serio G, Minelli M, Minardi
A, Scarcia G, Coradduzza G, Parmiani S. Specific sublingual immunotherapy
in atopic dermatitis. Results of a 6-year
follow-up of 35 consecutive patients. Allergol Immunopathol (Madr).
2000 Mar-Apr;28(2):54-62.
- Shaikh WA. A retrospective study on the safety
of immunotherapy in pregnancy. Clin Exp Allergy. 1993 Oct;23(10):857-60.
- Altintas D, Akmanlar N, Guneser S, Burgut
R, Yilmaz M, Bugdayci R, Aksungur P. Comparison between the use
of adsorbed and aqueous immunotherapy material in Dermatophagoides
pteronyssinus sensitive asthmatic children. Allergol Immunopathol
(Madr). 1999 Nov-Dec;27(6):309-17.
- Alvarez-Cuesta E, Gonzelez-Mancebo E. Immunotherapy
in bronchial asthma. Curr Opin Pulm Med. 2000 Jan;6(1):50-4.
Review.
- Tabar AI, Muro MD, Garcia BE, Alvarez MJ,
Acero S, Rico P, Olaguibel JM. Dermatophagoides pteronyssinus
cluster immunotherapy. A controlled trial of
safety and clinical efficacy. J Investig Allergol Clin Immunol.
1999 May-Jun;9(3):155-64.
- Ariano R, Kroon AM, Augeri G, Canonica GW,
Passalacqua G. Long-term treatment with allergoid immunotherapy
with Parietaria. Clinical and immunologic effects in a randomized,
controlled trial. Allergy. 1999 Apr;54(4):313-9.
- Vourdas D, Syrigou E, Potamianou P, Carat
F, Batard T, Andre C, Papageorgiou PS. Double-blind, placebo-controlled
evaluation of sublingual immunotherapy with standardized olive
pollen extract in pediatric patients with allergic rhinoconjunctivitis
and mild asthma due to olive pollen sensitization. Allergy. 1998
Jul;53(7):662-72.
- Ariano R, Panzani RC, Augeri G.
Efficacy and safety of oral immunotherapy in respiratory allergy
to Parietaria judaica pollen. A double-blind study. J Investig
Allergol Clin Immunol. 1998 May-Jun;8(3):155-60.
- Cook PR, Farias C. The safety of allergen
immunotherapy: a literature review. Ear Nose Throat J. 1998 May;77(5):378-9,
383-8. Review.
- Alvarez-Cuesta E, Hernandez Pena J. The safety
and efficiency of immunotherapy. J Investig Allergol Clin Immunol.
1997 Sep-Oct;7(5):358-9. Review.
- Laurent J, Smiejan JM, Bloch-Morot E, Herman
D. Safety of Hymenoptera venom rush immunotherapy. Allergy. 1997
Jan;52(1):94-6.
- Lockey RF. Adverse reactions associated with
skin testing and immunotherapy. Allergy Proc. 1995 Nov-Dec;16(6):293-6.
Review.
- Bousquet J, Michel FB. Safety considerations
in assessing the role of immunotherapy in allergic disorders.
Drug Saf. 1994 Jan;10(1):5-17. Review.
- Frew AJ. Injection immunotherapy. British
Society for Allergy and Clinical Immunology Working Party. BMJ.
1993 Oct 9;307(6909):919-23. Review.
- Tabar AI, Garcia BE, Rodriguez A, Olaguibel
JM, Muro MD, Quirce S. A prospective safety-monitoring study
of immunotherapy with biologically standardized extracts. Allergy.
1993 Aug;48(6):450-3.
- Schwartz HJ, Golden DB, Lockey RF. Venom
immunotherapy in the Hymenoptera-allergic pregnant patient. J
Allergy Clin Immunol. 1990 Apr;85(4):709-12.
- Norman PS. Safety of allergen immunotherapy.
J Allergy Clin Immunol. 1989 Oct;84(4 Pt 1):438-9.
- Greenberg MA, Kaufman CR, Gonzalez GE, Trusewych
ZP, Rosenblatt CD, SummersRJ. Late systemic-allergic reactions
to inhalant allergen immunotherapy. J Allergy Clin Immunol. 1988
Aug;82(2):287-90.
